Європейський Союз - естонська - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - temosolomiid - glioma; glioblastoma - antineoplastilised ained - temozolomide sun on näidustatud ravi:täiskasvanud patsientidel, kellel on äsja diagnoositud glioblastoma erüteem samaaegselt koos kiiritusravi (rt) ja hiljem monotherapy ravi;lapsed vanuses kolm aastat, noorukid ja täiskasvanud patsientidele, kellel on pahaloomuline glioma, nagu glioblastoma erüteem või anaplastic astrocytoma, näidates kordumise või progresseerumise pärast standardset ravi.

Європейський Союз - естонська - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastilised ained - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Європейський Союз - естонська - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastilised ained - onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. onbevzi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. lisateavet inimese epidermaalse kasvufaktori retseptori 2 (her2) seisundi kohta vt palun 5. jaotisest. onbevzi in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with onbevzi in combination with capecitabine. her2 staatuse kohta lisateabe saamiseks lugege palun 5. jaotist. onbevzi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. onbevzi, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. onbevzi in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. onbevzi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. onbevzi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Європейський Союз - естонська - EMA (European Medicines Agency)

fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - kõik muud ravitoimingud - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.

Європейський Союз - естонська - EMA (European Medicines Agency)

ology bioservices ireland ltd - gripiviirus (kogu virion, inaktiveeritud), mis sisaldab antigeeni: a / vietnam / 1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - gripivaktsiinid - aktiivne immuniseerimine gripiviiruse h5n1 alatüübi vastu. see näidustus põhineb immunogenicity andmeid teemasid alates vanusest 6 kuud aastast pärast manustamist kaks annust vaktsiini, mis on valmistatud alatüübi h5n1 tüve. vepacel tuleks kasutada vastavalt euroopa liidu arendus.

Європейський Союз - естонська - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastilised ained - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Європейський Союз - естонська - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - temosolomiid - glioma; glioblastoma - antineoplastilised ained - temomedac raske kapslid on näidustatud ravi:täiskasvanud patsientidel, kellel on äsja diagnoositud glioblastoma erüteem samaaegselt koos kiiritusravi (rt) ja hiljem monotherapy ravi;lapsed vanuses kolm aastat, noorukid ja täiskasvanud patsientidele, kellel on pahaloomuline glioma, nagu glioblastoma erüteem või anaplastic astrocytoma, näidates kordumise või progresseerumise pärast standardset ravi.

Європейський Союз - естонська - EMA (European Medicines Agency)

hexal ag - temosolomiid - glioma; glioblastoma - antineoplastilised ained - uute diagnoositud multiformse glioblastoomi täiskasvanud patsientide raviks koos kiiritusravi (rt) ja seejärel monoteraapiaga. ravi lapsed vanuses kolm aastat, noorukid ja täiskasvanud patsientidele, kellel on pahaloomuline glioma, nagu glioblastoma erüteem või anaplastic astrocytoma, näidates kordumise või progresseerumise pärast standardset ravi.

Європейський Союз - естонська - EMA (European Medicines Agency)

sandoz gmbh - temosolomiid - glioma; glioblastoma - antineoplastilised ained - uute diagnoositud multiformse glioblastoomi täiskasvanud patsientide raviks koos kiiritusravi (rt) ja seejärel monoteraapiaga. ravi lapsed vanuses kolm aastat, noorukid ja täiskasvanud patsientidele, kellel on pahaloomuline glioma, nagu glioblastoma erüteem või anaplastic astrocytoma, näidates kordumise või progresseerumise pärast standardset ravi.

Європейський Союз - естонська - EMA (European Medicines Agency)

endoceutics s.a. - prasterone - postmenopaus - teised suguhormoonid ja genitaalsüsteemi - intrarosa on näidustatud menopausijärgsetel naistel, kellel on mõõdukad kuni rasked sümptomid, villa- ja tupe atroofia raviks..